644
Participants
Start Date
January 31, 2024
Primary Completion Date
September 13, 2024
Study Completion Date
September 13, 2024
BNT162b2 (Omi XBB.1.5)/RIV
Combination of BNT162b2 (Omi XBB.1.5) and RIV
BNT162b2 (Omi XBB.1.5)
Licensed COVID-19 vaccine
RIV
Licensed recombinant influenza vaccine
Normal saline placebo
Normal saline (solution for injection)
Rochester Clinical Research, LLC, Rochester
GW Medical Faculty Associates, Washington D.C.
GW Vaccine Research Unit, Washington D.C.
Charlottesville Medical Research, Charlottesville
Clinical Research Atlanta, Stockbridge
Clinical Site Partners, LLC dba Flourish Research, Winter Park
Headlands Research Orlando, Orlando
Optimal Research, Melbourne
Indago Research & Health Center, Inc, Hialeah
JEM Research Institute, Atlantis
Clinical Research Associates Inc, Nashville
Centricity Research Columbus Ohio Multispecialty, Columbus
Optimal Research, Peoria
Bio-Kinetic Clinical Applications, LLC dba QPS-MO, Springfield
Bio-Kinetic Clinical Applications, LLD dba QPS-MO, Springfield
Bio-Kinetic Clinical Applications LLC DBA QPS-MO(Patient Screening Center), Springfield
SMS Clinical Research, Mesquite
DM Clinical Research- Cyfair, Houston
DM Clinical Research - Bellaire, Houston
DM Clinical Research - MDC, Tomball
Clinical Trials of Texas, LLC, San Antonio
IMA Clinical Research San Antonio, San Antonio
Las Vegas Clinical Trials, Las Vegas
Las Vegas Clinical Trials, North Las Vegas
Orange County Research Center, Lake Forest
Orange County Research Center, Tustin
Diablo Clinical Research, Inc., Walnut Creek
East-West Medical Research Institute, Honolulu
Clinical Research Consulting, Milford
ActivMed Practices & Research, LLC., Portsmouth
Lead Sponsor
Pfizer
INDUSTRY